SBSB
PGEN icon

Sullivan, Bruyette, Speros & Blaney’s Precigen PGEN Stock Holding History

Sullivan, Bruyette, Speros & Blaney’s Portfolio PGEN Stock Details PGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,209
Closed -$228K – 146
2016
Q3 		$228K Sell
8,209
-1,488
-15% -$39.3K 0.02% 130
2016
Q2 		$237K Buy
+9,697
New +$275K 0.02% 117

Other funds holding PGEN

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Sullivan, Bruyette, Speros & Blaney's PGEN Position: Q4 2016 in Review

Sullivan, Bruyette, Speros & Blaney sold out of Precigen (PGEN) in Q4 2016, closing a stake of 8,209 shares — an estimated $228K sold.

Sullivan, Bruyette, Speros & Blaney first reported a position in PGEN in Q2 2016 and held it in 2 quarters. The position peaked at $237K in Q2 2016. 171 funds tracked by Wall St. Rank hold PGEN as of Q4 2016.

  • Sullivan, Bruyette, Speros & Blaney reported no remaining Precigen position as of Q4 2016 after selling out during the quarter.
  • Sullivan, Bruyette, Speros & Blaney sold 8,209 Precigen shares in Q4 2016, an estimated $228K.
  • Sullivan, Bruyette, Speros & Blaney first reported a position in Precigen in Q2 2016 and held it in 2 quarters.
  • Sullivan, Bruyette, Speros & Blaney's Precigen position peaked at $237K in Q2 2016.
  • 171 funds tracked by Wall St. Rank held Precigen as of Q4 2016.

Based on Sullivan, Bruyette, Speros & Blaney's 13F filing for Q4 2016, filed 3 Feb 2017.